Previous 10 | Next 10 |
2023-06-21 13:20:27 ET Gainers: Argo Blockchain ( ARBK ) +32% . Ocean Biomedical ( OCEA ) +21% . Mullen Automotive ( MULN ) +20% . Freightos Limited ( CRGO ) +18% . PureCycle Technologies ( PCT ) +17% . PetVivo Holdings ( P...
2023-06-21 10:07:44 ET Gainers: Ocean Biomedical ( OCEA ) +43% . PetVivo Holdings ( PETV ) +23% . Patterson Companies ( PDCO ) +14% . Zentalis Pharmaceuticals ( ZNTL ) +5% . RenovoRx ( RNXT ) +4% . Losers: uniQure ( ...
2023-06-21 08:24:41 ET Dutch biotech uniQure N.V. ( NASDAQ: QURE ) fell ~30% pre-market Wednesday after announcing interim data from its Phase 1/2 trial for AMT-130 in the treatment of neurogenerative disorder Huntington’s disease. Citing up to 24 months of follow-up ...
2023-06-21 08:14:39 ET uniQure ( QURE ) -29% announces update on U.S. phase I/II clinical trial of AMT-130 gene therapy for the treatment of huntington’s disease . VCI Global Limited ( VCIG ) -20% . Red Cat Holdings ( RCAT ) -13% . voxeljet (...
~ AMT-130 continues to be generally well-tolerated across both dose cohorts ~ ~ Patients treated with AMT-130 show preserved function compared to baseline and clinical benefits relative to natural history of the disease ~ ~ Neurofilament Light Chain (NfL) in cerebrospinal fluid ...
LEXINGTON, Mass. and AMSTERDAM, June 20, 2023 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, announced the achievement of a $100 million milestone associated with the first commercial s...
CSL Behring Announces the First Patient Has Received FDA-Approved HEMGENIX® (etranacogene dezaparvovec-drlb) for Hemophilia B PR Newswire HEMGENIX ® , the first and only FDA approved gene therapy for hemophilia B, has been proven to elevate and sustain factor IX ...
2023-05-22 17:38:02 ET Summary uniQure secured FDA approval late last year and EMA approval in Q1 2023 for its AMT-061 Hemophilia B treatment. This paves the way for its commercialization in the US and EU. It also has a healthy R&D pipeline, with its Huntington’s diseas...
2023-05-20 09:19:55 ET Summary uniQure's strong financial performance and remarkable revenue growth highlight the company's continued upward trajectory, making it a promising investment opportunity. Innovative gene therapies such as HEMGENIX for hemophilia B and AMT-130 for Huntin...
2023-05-15 08:26:38 ET Dutch biotech uniQure N.V. ( NASDAQ: QURE ) added ~7% pre-market Monday after announcing an agreement to sell a portion of royalty rights expected to receive from Australian drugmaker CSL Limited ( OTCQX:CSLLY ) in relation to the gene therapy Hemgenix...
News, Short Squeeze, Breakout and More Instantly...
~ uniQure maintains preferential access to industry-leading manufacturing capabilities to support its pipeline of gene therapy candidates ~ ~ Immediate reduction in cash burn, projected to save $40 million annually ~ LEXINGTON, Mass. and AMSTERDAM, July 23, 2024 (GLOBE NEWSWIRE) -...
A look at the top 10 most actives in the United States Kazia Therapeutics Limited (KZIA) rose 248.0% to $0.6682 on volume of 430,252,408 shares Maxeon Solar Technologies Ltd. (MAXN) fell 15.0% to $0.2108 on volume of 237,403,092 shares NVIDIA Corporation (NVDA) rose 2.7% to $134.91 on vol...
A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) rose 2.5% to $131.38 on volume of 280,159,738 shares Maxeon Solar Technologies Ltd. (MAXN) fell 8.1% to $0.248 on volume of 217,585,873 shares Tesla Inc. (TSLA) rose 3.7% to $262.33 on volume of 159,323,492 s...